- Home
- VEL vs NVCT Comparison
VEL vs NVCT Comparison
Compare VEL & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | NVCT |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 765.5M | 721.2M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VEL | NVCT |
|---|---|---|
| Price | $17.18 | $19.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $22.00 | $10.00 |
| AVG Volume (30 Days) | 89.7K | ★ 589.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.98 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.01 | N/A |
| Revenue Next Year | $19.02 | N/A |
| P/E Ratio | $30.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.19 | $5.55 |
| 52 Week High | $21.40 | $29.28 |
Technical Indicators
Market Signals| Indicator | VEL | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 54.68 |
| Support Level | $16.97 | $18.02 |
| Resistance Level | $17.98 | $29.28 |
| Average True Range (ATR) | 0.53 | 1.26 |
| MACD | -0.07 | -0.50 |
| Stochastic Oscillator | 4.97 | 38.24 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. Company operates in a large fragmented market with substantial demand for financing and limited supply of institutional financing alternative The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.